Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zd-4190 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 18/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 15/20 | 1.00 |
| ▸ | FLT1 | P17948 | 15/20 | 1.00 |
| ▸ | FLT4 | P35916 | 12/20 | 1.00 |
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 5/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 5/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 5/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 0.70 |
| ▸ | KIF5B | P33176 | 2/20 | 0.70 |
| ▸ | TEK | Q02763 | 2/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040728 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4EGFR | |
| Zd-4190 Free Base SCHEMBL29729304 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4EGFR | |
| Zd-4190 Free Base SCHEMBL29363192 | 0.99 | KDR (0.98) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL15445258 | 0.89 | KDR (0.80) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL5177296 | 0.89 | KDR (0.79) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL17520360 | 0.85 | KDR (0.83) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL7459925 | 0.85 | KDR (0.82) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL23117893 | 0.84 | KDR (0.73) | KDRFGFR1FLT1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL7455417 | 0.84 | KDR (0.81) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL7864780 | 0.84 | KDR (0.83) | KDRFGFR1FLT1FLT4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 994 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539924-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | Novocure GmbH (CH) | 2025-04-23 | — | — | EP | claimed |
| CN-119451723-A | Compositions, systems, and methods for treating cancer using a tumor treating electric field and a VEGF inhibitor | 诺沃库勒有限责任公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2023248139-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | NOVOCURE GMBH (CH) | 2023-12-28 | — | — | WO | claimed |
| US-20230405316-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | NOVOCURE GMBH (CH) | 2023-12-21 | — | — | US | claimed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | claimed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| EP-1272186-B1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-28 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| EP-1658849-A2 | Therapeutic combinations of antihypertensive and antiangiogenic agents | AstraZeneca AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1272186-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001074360-A1 | THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | KDR 2036/4885FGFR1 632/4885FLT1 2214/4885 |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | AGER, CKMT1A; CKMT1B, GLA | KDR 3861/4885FGFR1 4156/4885FLT1 4241/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | KDR 2/4885FGFR1 30/4885FLT1 3/4885 |
| US-20030144298-A1 | Using a combination of an angiogenisis inhibitor and a hypotensive agent for use in treating diseases associated with angiogenesis; an endothelial growth factor receptor tyrosine kinase inhibitor; antidiabetic, -arthritis agents | TEK, TIE1, FLT1 | KDR 5/4885FGFR1 9/4885FLT1 3/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | KDR 6/4885FGFR1 87/4885FLT1 5/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | KDR 1358/4885FGFR1 2508/4885FLT1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.